Sophie Pierrin-Lepinard
Managing Director @ KREAXI
Paris, France
Sophie Pierrin-Lepinard is a seed investor at KREAXI in Paris focused on Health Care and Medical. Sophie Pierrin-Lepinard - Managing Director @ KREAXI
- Total investments:
- 4
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Sophie Pierrin-Lepinard invests in
Stages Sophie Pierrin-Lepinard invests in
Countries Sophie Pierrin-Lepinard invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 4 (100%)
- Medical 2 (50%)
- Biotechnology 2 (50%)
- Medical Device 2 (50%)
- Big Data 1 (25%)
Stage
- Seed 2 (50%)
- Series A 2 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
DESKi
|
DESKi, “learn” in Breton, is a young and innovative company, combining a strong expertise in both medical imaging and artificial intelligence. DESKi works hand in hand with medical practitioners and researchers to develop automated, accurate, and data-driven image analysis tools for an enhanced patient care. | $6M / Seed / Jun 18, 2025 | |
Ciliatech
|
Ciliatech is a medtech company specialized in ophthalmology, develops a new class of implant to address the increasing need to treat glaucoma durably and with very minimal adverse effects. | $1.9M / Series A / Apr 25, 2023 | |
DAMAE Medical
|
Damae Medical is a Paris, France-based medtech company. It has developed a medical device capable of seeing biological tissues in depth, at a cellular level and in vivo. This innovative optical imaging technology will especially allow dermatologists to evaluate in a precise, efficient and rapid way malignancy of tumors by a simple contact with thesurface of the skin. DAMAE Medical’s mission is to put the great power of bio-photonics at the service of opening new opportunities in medical imaging and diagnosis. | $5.7M / Series A / Feb 03, 2022 | |
Lucine
|
Lucine has the ambition to transform and improve patient’s health. Their main therapeutic area is pain. The product, a digital therapeutic is able to relieve patient’s pain in 5 minutes through active substances allowing an analgesic neurostimulation. Customized, their solution is adapted to each patient thanks to an instantaneous measurement andanalysis of the pain by facial, vocal and postural recognition. | $6.5M / Seed / Nov 18, 2020 |
Co-Investors
About KREAXI
Kreaxi is a management company specializing for over 30 years in investing in the capital of innovative and technological startups with high potential.
KREAXI Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Isabelle BOU-ANTOUN
Managing Director
|
|||
|
Sophie Pierrin-Lepinard
Managing Director
|
|||
Anne-Lise Flandin
Assistant de gestion
|
|||
Fabrice Lacroix
Investment Committee Member
|
|||
Flora Loger
Head of Legal and Internal Control
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Sophie Pierrin-Lepinard invest in?
Sophie Pierrin-Lepinard invests primarily in Health Care, Medical and Biotechnology startups, most often at Seed and Series A stage. Most of the 4 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Sophie Pierrin-Lepinard?
Public channels for Sophie Pierrin-Lepinard include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Sophie Pierrin-Lepinard last invest?
The most recent investment recorded for Sophie Pierrin-Lepinard closed in Jun 2025. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
